Rating Rationale
March 29, 2018 | Mumbai
Mylan Laboratories Limited
Rating outlook revised to 'Stable', rating reaffirmed
 
Rating Action
Total Bank Loan Facilities Rated Rs.805 Crore
Long Term Rating CRISIL AA-/Stable (Outlook revised from 'Negative' and rating reaffirmed)
 
Non-Convertible Bonds Aggregating Rs.2480.34 Crore CRISIL AA-/Stable (Outlook revised from 'Negative' and rating reaffirmed) 
1 crore = 10 million
Refer to annexure for Details of Instruments & Bank Facilities
Detailed Rationale

CRISIL has revised its rating outlook on the long-term bank facilities and non-convertible bonds of Mylan Laboratories Ltd (Mylan Labs) to 'Stable' from 'Negative', and reaffirmed the rating at 'CRISIL AA-'.
 
The outlook revision is driven by expectation that closure of warning letters issued in August 2015 to three of the company's facilities in Bengaluru, enhances revenue visibility from these units of Mylan Labs and mitigate pressure on operating profitability given lower remediation costs going forward. The warning letters were closed in July 2017 based on corrective actions taken by the company, while the Nashik (Maharashtra) facility that was issued warning letter in April 2017 remains under remediation. Increased product approvals from Bengaluru facilities and ramp up in the female healthcare business (acquired in November 2015) are expected to result in a cumulative annual growth rate of 10-15% from these businesses over the medium term, albeit on a small base. However, pricing pressure in international market is likely to constrain annual growth in the remaining business to 3-4%; resulting in overall growth of 4-5% over the medium term. Revenue remained flattish in fiscal 2017 on account of 6% de-growth in formulation exports due to intensified competition in the export markets.
 
The rating action also factors in the expectation of gradual improvement in operating profitability that has sustained at a healthy 18-20% in the last three fiscals, despite regulatory issues. Financial risk profile is expected to remain healthy over the medium term given modest debt-funded capital expenditure (capex) and robust operating performance. Capex of around Rs 900 crore incurred in fiscal 2017 was largely funded through internal accrual. Over the medium term, capex is expected to remain in the Rs 600-700 crore per annum range and will be entirely funded through internal accrual.
 
The rating continues to reflect Mylan Labs' strong business risk profile supported by an established market position, presence in various therapeutic segments, and geographical diversity. The rating also factors in healthy operating profitability and strong financial risk profile because of high annual cash generation, adequate debt protection metrics, and a comfortable capital structure. Furthermore, the company gets operational and financial support from parent, Mylan NV (Mylan; formerly Mylan Inc, rated 'BBB-/Stable' by S&P Global Ratings). These strengths are partially offset by working capital-intensive operations and exposure to increasing regulatory scrutiny and competition in the global generics market.

Analytical Approach

* CRISIL has treated the compulsorily convertible debentures issued to Mylan Labs for funding the acquisition of Agila Specialties Pvt Ltd (Agila) as part of networth as these are compulsorily convertible into equity.
* Goodwill arising out of the Agila and Jai Pharma Ltd (JPL) acquisitions has been amortised over the five years from the date of the respective acquisitions.

Key Rating Drivers & Detailed Description
Strengths
* Established market position supported by diverse revenue streams: Mylan Labs is one of the largest manufacturers and suppliers of active pharmaceutical ingredients (APIs) in the world. The company caters to a variety of therapeutic categories and has a diverse product profile oriented towards difficult-to-manufacture and complex products. Additionally, it has an established presence both in regulated and semi-regulated markets. In the regulated markets, products are sold mainly through parent, whereas sales in semi-regulated markets are institutional and hence tender-based.
 
* Healthy operating profitability: Margin was sustained at 18-20% over the three years through fiscal 2017 and is estimated to be at similar level for fiscal 2018, despite temporary lower contribution from Agila and one-time expenditure towards remediation expenses for this company's injectable facilities. Profitability was supported by an established product profile, and healthy operating efficiency. While revenue has remained flattish in fiscal 2017 and is estimated to grow at 2-3% in fiscal 2018, it had registered a strong compound annual growth of 24% between fiscals 2011 and 2016. This, along with steady profitability, has enabled steady cash flow from operations.
 
* Healthy financial risk profile that is expected to improve further over medium term: Gearing and the total outside liabilities to tangible networth ratio improved to an estimated 0.50 time and 0.76 time, respectively, as on March 31, 2018, from 0.79 time and 1.44 times, respectively, as on March 31, 2013, despite two large-sized acquisitions. This was largely due to compulsory convertible debentures (treated as equity) of Rs 5026.69 crore subscribed to by Mylan Labs in fiscal 2014 for funding the Agila acquisition, and by equity infusion of Rs 2346 crore in fiscal 2016 for the JPL acquisition. However, delay in scale-up at acquired facilities on account of regulatory issues resulted in moderation in debt to earnings before interest tax depreciation and amortisation (EBITDA) and return on capital employed (RoCE) during the same period; debt to EBITDA and RoCE are estimated at 2.8 times and 2%, respectively, for fiscal 2018 (1.7 times and 25%, respectively, for fiscal 2013). Debt protection metrics have also moderated, reflected in estimated interest coverage and net cash accrual to adjusted debt ratios of 2.12 times and 0.18 times for fiscal 2018. Gearing is expected to continue at a similar level while debt to EBITDA, RoCE, and debt protection metrics are expected to gradually improve over the medium term, supported by healthy cash generation.
 
* Strong operational and financial support from parent: Mylan Labs benefits from its strong operational and financial linkages with Mylan, which is among the top five generics players globally. The company, with its strong research and development (R&D) capabilities and low-cost manufacturing base, serves as an important centre and manufacturing base for Mylan. Parent also provides financial support through external commercial borrowing to partly fund capex or working capital requirements. Past acquisitions have also been fully funded by parent through a mix of debt and equity.
 
Weakness
* Working capital-intensive operations: Working capital requirement is large due to significant institutional sales. Receivables and inventory averaged 3.5 months and 5.5 months, respectively, between fiscals 2013 and 2017. Inventory is sizeable on account of increase in manufacture of finished dosage form (FDF) products over the past two fiscals. Realisation period is longer for in-country tender sales; hence, with an increasing proportion of in-country sales, receivables level may remain high. Also, an expanding presence in the emerging markets is likely to stretch receivables owing to repatriation issues. Any further stretch in receivables could increase working capital requirement and will hence remain a key rating monitorable.
 
* Exposure to increasing competition and pricing pressures in the global generics market: The company remains exposed to increasing competition in the international generics market and to currency fluctuations in emerging markets. Around 54% of revenue was derived from the regulated markets in fiscal 2017. Aggressive tactics adopted by innovator companies through introduction of authorised generics, and healthcare cost containment measures by the US government have intensified competition. In addition, players in the regulated markets of the US and Europe are vulnerable to pricing pressures, owing to the entry of several cost-competitive Indian players and the increased bargaining power of distribution channels due to their consolidation. Also, with the growing competition, substantial investments in infrastructure and R&D could impact the margin.
Outlook: Stable

CRISIL believes Mylan Labs' operating performance will gradually improve over the medium term driven by steady revenue growth and healthy operating profitability. Financial risk profile is expected to remain strong, supported by healthy gearing and adequate debt protection metrics.
 
Upside scenario
* Higher-than-expected revenue growth driven by faster new drug approvals at Agila facilities, and/or improvement in female healthcare business, among others
* Increase in operating profitability on sustained basis to earlier levels of 21-22% on the back of better revenue growth
* Earlier-than-expected increase in RoCE to over 10%, most likely driven by faster realisation of acquisition benefits given the resolution in regulatory issues for Agila facilities
 
Downside scenario
* Sustained decline in operating profitability to below 17%, most likely on account of any new regulatory issues or escalation of existing warning letter on Nashik plant to import alert
* Material increase in debt due to higher-than-anticipated capital expenditure (capex) or acquisitions, or a stretched working capital cycle

About the Company

Mylan Labs, incorporated in 1984 as Matrix Laboratories Ltd (Matrix), commenced operations by manufacturing APIs for the Acquired Immune Deficiency Syndrome (AIDS) drugs for large domestic and global generic players. Mylan acquired Matrix in 2007, post which it was renamed Mylan Labs and became a subsidiary of Mylan.
 
Mylan Labs is one of the world's largest API manufacturers and produces APIs for use in its own pharmaceutical products, and for third parties. The APIs cater to a wide range of categories, including anti-bacterials, central nervous system agents, antihistamine/anti-asthmatics, cardiovasculars, anti-virals, anti-diabetics, anti-fungals, proton pump inhibitors, and pain management drugs. The company also manufactures non-ARV (anti-retro viral) FDF products that are marketed and sold to third parties by other Mylan companies around the world.
 
Mylan has 25 facilities in India, including nine API facilities, eight oral solid dosage plants, and eight injectables units. Sixteen facilities, including eight API facilities, are approved by the US FDA. The company also has three R&D sites- one each in Hyderabad, Bengaluru and Ahmedabad. Some of the key markets served from India include Australia, Canada, Europe, Japan, New Zealand, US and Rest of the World, including Africa.
 
On December 5, 2013, Mylan completed the acquisition of Agila's injectable business from Strides Arcolab Ltd for nearly USD 1.75 billion. Agila is a leading global manufacturer of speciality injectables focused on oncolytics, penems, penicillin, cephalosporins, and ophthalmics, with nine manufacturing facilities across India, Poland, and Brazil. Mylan Labs completed the acquisition of the female healthcare business of the erstwhile Famy Care Ltd on November 21, 2015, after receipt of regulatory approvals.

Key Financial Indicators^
Particulars Unit 2017 2016
Revenue Rs. cr. 9383 9338
Profit after tax Rs. cr. -559 -136
PAT margin % -5.6 -1.4
Adjusted debt/adjusted networth Times 0.50 0.50
Adjusted interest coverage Times 2.15 2.70
^CRISIL adjusted numbers

Any other information: Not applicable

Note on complexity levels of the rated instrument:
CRISIL complexity levels are assigned to various types of financial instruments. The CRISIL complexity levels are available on www.crisil.com/complexity-levels. Users are advised to refer to the CRISIL complexity levels for instruments that they consider for investment. Users may also call the Customer Service Helpdesk with queries on specific instruments.
Annexure - Details of Instrument(s)
ISIN Name of Instrument Date of Allotment Coupon Rate (%) Maturity Date Issue Size
(Rs. Cr)
Rating Assigned
with Outlook
INE604D08010 Bonds 10-Nov-15 10.25% 10-Nov-25 2480.34 CRISIL AA-/Stable
NA Cash Credit* NA NA NA 776.4 CRISIL AA-/Stable
NA Proposed Long Term Bank Loan facility NA NA NA 28.6 CRISIL AA-/Stable
*Interchangeable with working capital demand loan/packing credit/bill discounting/letter of credit/bank guarantee
Annexure - Rating History for last 3 Years
  Current 2018 (History) 2017  2016  2015  Start of 2015
Instrument Type Quantum Rating Date Rating Date Rating Date Rating Date Rating Rating
Non Convertible Bonds  LT  2510  CRISIL AA-/Stable    No Rating Change    No Rating Change    No Rating Change  21-08-15  CRISIL AA-/Negative  -- 
Short Term Debt  ST    --    --    --  27-10-16  Withdrawal    No Rating Change  CRISIL A1+ 
Fund-based Bank Facilities  LT/ST  805  CRISIL AA-/Stable    No Rating Change    No Rating Change    No Rating Change  21-08-15  CRISIL AA-/Negative  CRISIL AA-/Stable 
Table reflects instances where rating is changed or freshly assigned. 'No Rating Change' implies that there was no rating change under the release.
Annexure - Details of various bank facilities
Current facilities Previous facilities
Facility Amount (Rs.Crore) Rating Facility Amount (Rs.Crore) Rating
Cash Credit* 776.4 CRISIL AA-/Stable Cash Credit* 776.4 CRISIL AA-/Negative
Proposed Long Term Bank Loan Facility 28.6 CRISIL AA-/Stable Proposed Long Term Bank Loan Facility 28.6 CRISIL AA-/Negative
Total 805 -- Total 805 --
*Interchangeable with working capital demand loan/packing credit/bill discounting/letter of credit/bank guarantee
Links to related criteria
CRISILs Approach to Financial Ratios
CRISILs Bank Loan Ratings - process, scale and default recognition
Rating criteria for manufaturing and service sector companies
Rating Criteria for the Pharmaceutical Industry
Criteria for Notching up Stand Alone Ratings of Companies based on Parent Support
Mapping global scale ratings onto CRISIL scale

For further information contact:
Media Relations
Analytical Contacts
Customer Service Helpdesk
Saman Khan
Media Relations
CRISIL Limited
D: +91 22 3342 3895
B: +91 22 3342 3000
saman.khan@crisil.com

Naireen Ahmed
Media Relations
CRISIL Limited
D: +91 22 3342 1818
B: +91 22 3342 3000
naireen.ahmed@crisil.com

Jyoti Parmar
Media Relations
CRISIL Limited
D: +91 22 3342 1835
B: +91 22 3342 3000
 jyoti.parmar@crisil.com

Anuj Sethi
Senior Director - CRISIL Ratings
CRISIL Limited
D:+91 44 6656 3100
anuj.sethi@crisil.com


Akshay Chitgopekar
Director - CRISIL Ratings
CRISIL Limited
D:+91 22 4097 8309
akshay.chitgopekar@crisil.com


Sundeep Allamraju
Rating Analyst - CRISIL Ratings
CRISIL Limited
D:+91 22 3342 8360
Sundeep.Allamraju@crisil.com
Timings: 10.00 am to 7.00 pm
Toll free Number:1800 267 1301

For a copy of Rationales / Rating Reports:
CRISILratingdesk@crisil.com
 
For Analytical queries:
ratingsinvestordesk@crisil.com


 

Note for Media:
This rating rationale is transmitted to you for the sole purpose of dissemination through your newspaper / magazine / agency. The rating rationale may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL. However, CRISIL alone has the sole right of distribution (whether directly or indirectly) of its rationales for consideration or otherwise through any media including websites, portals etc.


About CRISIL Limited

CRISIL is a leading agile and innovative, global analytics company driven by its mission of making markets function better. We are India’s foremost provider of ratings, data, research, analytics and solutions. A strong track record of growth, culture of innovation and global footprint sets us apart. We have delivered independent opinions, actionable insights, and efficient solutions to over 1,00,000 customers.
 
We are majority owned by S&P Global Inc., a leading provider of transparent and independent ratings, benchmarks, analytics and data to the capital and commodity markets worldwide.
 
For more information, visit www.crisil.com 


Connect with us: TWITTER | LINKEDIN | YOUTUBE | FACEBOOK

About CRISIL Ratings
CRISIL Ratings is part of CRISIL Limited (“CRISIL”). We pioneered the concept of credit rating in India in 1987. CRISIL is registered in India as a credit rating agency with the Securities and Exchange Board of India (“SEBI”). With a tradition of independence, analytical rigour and innovation, CRISIL sets the standards in the credit rating business. We rate the entire range of debt instruments, such as, bank loans, certificates of deposit, commercial paper, non-convertible / convertible / partially convertible bonds and debentures, perpetual bonds, bank hybrid capital instruments, asset-backed and mortgage-backed securities, partial guarantees and other structured debt instruments. We have rated over 24,500 large and mid-scale corporates and financial institutions. CRISIL has also instituted several innovations in India in the rating business, including rating municipal bonds, partially guaranteed instruments and microfinance institutions. We also pioneered a globally unique rating service for Micro, Small and Medium Enterprises (MSMEs) and significantly extended the accessibility to rating services to a wider market. Over 1,10,000 MSMEs have been rated by us.


CRISIL PRIVACY NOTICE

CRISIL respects your privacy. We use your contact information, such as your name, address, and email id, to fulfil your request and service your account and to provide you with additional information from CRISIL and other parts of S&P Global Inc. and its subsidiaries (collectively, the “Company) you may find of interest.

For further information, or to let us know your preferences with respect to receiving marketing materials, please visit https://www.crisil.com/en/home/privacy-and-cookie-notice.html. You can view the Company’s Customer Privacy at https://www.spglobal.com/corporate-privacy-policy

Last updated: April 2016


DISCLAIMER

This disclaimer forms part of and applies to each credit rating report and/or credit rating rationale that we provide (each a “Report”). For the avoidance of doubt, the term “Report” includes the information, ratings and other content forming part of the Report. The Report is intended for the jurisdiction of India only. This Report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the Report is to be construed as CRISIL providing or intending to provide any services in jurisdictions where CRISIL does not have the necessary licenses and/or registration to carry out its business activities referred to above. Access or use of this Report does not create a client relationship between CRISIL and the user.

We are not aware that any user intends to rely on the Report or of the manner in which a user intends to use the Report. In preparing our Report we have not taken into consideration the objectives or particular needs of any particular user. It is made abundantly clear that the Report is not intended to and does not constitute an investment advice. The Report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind or otherwise enter into any deal or transaction with the entity to which the Report pertains. The Report should not be the sole or primary basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).

Ratings from CRISIL Rating are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, hold, or sell any securities / instruments or to make any investment decisions. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. CRISIL assumes no obligation to update its opinions following publication in any form or format although CRISIL may disseminate its opinions and analysis. CRISIL rating contained in the Report is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment or other business decisions. The recipients of the Report should rely on their own judgment and take their own professional advice before acting on the Report in any way.

Neither CRISIL nor its affiliates, third party providers, as well as their directors, officers, shareholders, employees or agents (collectively, “CRISIL Parties”) guarantee the accuracy, completeness or adequacy of the Report, and no CRISIL Party shall have any liability for any errors, omissions, or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the Report. EACH CRISIL PARTY DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY, SUITABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall any CRISIL Party be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the Report even if advised of the possibility of such damages.

CRISIL Ratings may receive compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors. CRISIL’s public ratings and analysis as are required to be disclosed under the regulations of the Securities and Exchange Board of India (and other applicable regulations, if any) are made available on its web sites, www.crisil.com (free of charge). Reports with more detail and additional information may be available for subscription at a fee – more details about CRISIL ratings are available here: www.crisilratings.com.

CRISIL and its affiliates do not act as a fiduciary. While CRISIL has obtained information from sources it believes to be reliable, CRISIL does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives and / or relies in its Reports. CRISIL keeps certain activities of its business units separate from each other in order to preserve the independence and objectivity of the respective activity. As a result, certain business units of CRISIL may have information that is not available to other CRISIL business units. CRISIL has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process. CRISIL has in place a ratings code of conduct and policies for analytical firewalls and for managing conflict of interest. For details please refer to: https://www.crisil.com/en/home/our-businesses/ratings/regulatory-disclosures/highlighted-policies.html

CRISIL’s rating criteria are generally available without charge to the public on the CRISIL public web site, www.crisil.com. For latest rating information on any instrument of any company rated by CRISIL you may contact CRISIL RATING DESK at CRISILratingdesk@crisil.com, or at (0091) 1800 267 1301.

This Report should not be reproduced or redistributed to any other person or in any form without a prior written consent of CRISIL.

All rights reserved @ CRISIL